Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor…
| Price | $0.18 |
|---|---|
| Market cap | $1.9M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | AMEX |
| 52-week range | 0.1-1.09 |
| Beta | -1.07 |
Explore AZTR's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.